Studies suggest that platelets from lung cancer patients can carry fusion transcripts from tumor cells, and monitoring EML4-ALK rearrangement fusion transcripts can predict the therapeutic response to ALK inhibitors in lung cancer patients [88]. Here, EML4 is linked to lung carcinoma.